Anticoagulation in nonvalvular atrial fibrillation.
Atrial fibrillation is a common cardiac arrhythmia. Management of atrial fibrillation should focus on prevention of thromboembolic complications and the treatment of arrhythmia related symptoms. This article will discuss anticoagulant therapy in nonvalvular atrial fibrillation and review results from several controlled trials.
Borresen
T
T
D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000150:complications / Q000628:therapy*; D016893:Carotid Stenosis / Q000150:complications / Q000517:prevention & control; D002543:Cerebral Hemorrhage / Q000139:chemically induced; D002561:Cerebrovascular Disorders / Q000209:etiology / Q000517:prevention & control; D002986:Clinical Trials as Topic; D004554:Electric Countershock; D006801:Humans; D002542:Intracranial Embolism and Thrombosis / Q000150:complications / Q000517:prevention & control*; D008875:Middle Aged; D012008:Recurrence; D012307:Risk Factors
D000925:Anticoagulants